INNOVENT BIO Surges 6% on Robust H1 Earnings, Sets Ambitious 2030 Revenue Target

Stock News08-26 09:28

Shares of INNOVENT BIO (01801) opened more than 6% higher on Thursday, extending gains to 6.49% at HK$106.60 with turnover reaching HK$28.73 million in early trading.

The rally follows the company's release of its 2026 interim results, which showed total revenue of RMB 8.618 billion under International Financial Reporting Standards (IFRS), representing a year-on-year increase of 44.8%. Product revenue climbed 56.7% to RMB 8.202 billion, while net profit for the period surged 50.2% to RMB 1.253 billion, already surpassing the full-year 2025 profit level within just the first half.

The strong performance was driven by the continued success of the company's "dual-engine" strategy focusing on oncology and chronic disease treatments. The commercial product portfolio has now expanded to include 20 drugs.

In the interim report, INNOVENT BIO also outlined its development goals for 2030, targeting total revenue between RMB 35 billion and RMB 40 billion. On the global innovation front, the company aims to advance at least five molecules into global multi-regional Phase III trials by 2030, achieve product launches in key European and US markets, and begin generating overseas product revenue.

Additionally, INNOVENT BIO officially announced its third major strategic transformation, transitioning from a leading Chinese biopharmaceutical company to a globally competitive first-tier biopharmaceutical enterprise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114601608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114601608","market":"sh","top_or_hot":-1,"title":"INNOVENT BIO Surges 6% on Robust H1 Earnings, Sets Ambitious 2030 Revenue Target","media":"Stock News","content":"<p>Shares of <b>INNOVENT BIO</b> (<b>01801</b>) opened more than 6% higher on Thursday, extending gains to 6.49% at HK$106.60 with turnover reaching HK$28.73 million in early trading.<br><br>The rally follows the company's release of its 2026 interim results, which showed total revenue of RMB 8.618 billion under International Financial Reporting Standards (IFRS), representing a year-on-year increase of 44.8%. Product revenue climbed 56.7% to RMB 8.202 billion, while net profit for the period surged 50.2% to RMB 1.253 billion, already surpassing the full-year 2025 profit level within just the first half.<br><br>The strong performance was driven by the continued success of the company's \"dual-engine\" strategy focusing on oncology and chronic disease treatments. The commercial product portfolio has now expanded to include 20 drugs.<br><br>In the interim report, <b>INNOVENT BIO</b> also outlined its development goals for 2030, targeting total revenue between RMB 35 billion and RMB 40 billion. On the global innovation front, the company aims to advance at least five molecules into global multi-regional Phase III trials by 2030, achieve product launches in key European and US markets, and begin generating overseas product revenue.<br><br>Additionally, <b>INNOVENT BIO</b> officially announced its third major strategic transformation, transitioning from a leading Chinese biopharmaceutical company to a globally competitive first-tier biopharmaceutical enterprise.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOVENT BIO Surges 6% on Robust H1 Earnings, Sets Ambitious 2030 Revenue Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOVENT BIO Surges 6% on Robust H1 Earnings, Sets Ambitious 2030 Revenue Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-26 09:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>INNOVENT BIO</b> (<b>01801</b>) opened more than 6% higher on Thursday, extending gains to 6.49% at HK$106.60 with turnover reaching HK$28.73 million in early trading.<br><br>The rally follows the company's release of its 2026 interim results, which showed total revenue of RMB 8.618 billion under International Financial Reporting Standards (IFRS), representing a year-on-year increase of 44.8%. Product revenue climbed 56.7% to RMB 8.202 billion, while net profit for the period surged 50.2% to RMB 1.253 billion, already surpassing the full-year 2025 profit level within just the first half.<br><br>The strong performance was driven by the continued success of the company's \"dual-engine\" strategy focusing on oncology and chronic disease treatments. The commercial product portfolio has now expanded to include 20 drugs.<br><br>In the interim report, <b>INNOVENT BIO</b> also outlined its development goals for 2030, targeting total revenue between RMB 35 billion and RMB 40 billion. On the global innovation front, the company aims to advance at least five molecules into global multi-regional Phase III trials by 2030, achieve product launches in key European and US markets, and begin generating overseas product revenue.<br><br>Additionally, <b>INNOVENT BIO</b> officially announced its third major strategic transformation, transitioning from a leading Chinese biopharmaceutical company to a globally competitive first-tier biopharmaceutical enterprise.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1114601608","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114601608","pubTimestamp":1787707707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of INNOVENT BIO (01801) opened more than 6% higher on Thursday, extending gains to 6.49% at HK$106.60 with turnover reaching HK$28.73 million in early trading.The rally follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","KCAI":"KraneShares China Alpha Index ETF","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1589":"北水核心资产","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK4588":"碎股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","01801":"信达生物","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV"},"translate_title":"信达生物上半年盈利强劲，股价飙升 6%，设定雄心勃勃的 2030 年收入目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"01801":1,"VXUS":1,"KURE":1},"content_text":"Shares of INNOVENT BIO (01801) opened more than 6% higher on Thursday, extending gains to 6.49% at HK$106.60 with turnover reaching HK$28.73 million in early trading.The rally follows the company's release of its 2026 interim results, which showed total revenue of RMB 8.618 billion under International Financial Reporting Standards (IFRS), representing a year-on-year increase of 44.8%. Product revenue climbed 56.7% to RMB 8.202 billion, while net profit for the period surged 50.2% to RMB 1.253 billion, already surpassing the full-year 2025 profit level within just the first half.The strong performance was driven by the continued success of the company's \"dual-engine\" strategy focusing on oncology and chronic disease treatments. The commercial product portfolio has now expanded to include 20 drugs.In the interim report, INNOVENT BIO also outlined its development goals for 2030, targeting total revenue between RMB 35 billion and RMB 40 billion. On the global innovation front, the company aims to advance at least five molecules into global multi-regional Phase III trials by 2030, achieve product launches in key European and US markets, and begin generating overseas product revenue.Additionally, INNOVENT BIO officially announced its third major strategic transformation, transitioning from a leading Chinese biopharmaceutical company to a globally competitive first-tier biopharmaceutical enterprise.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114601608","isCrawlerRequest":true}